Clinical Research Details Clinical Research MBPS205: A Phase 2b, Multicentre, Multinational, Placebo-controlled, Double-blind, Dose-finding Study in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with BPS804 Study Description The purpose of this study is to learn about the effects of a research drug, BPS804, to find the best dose for treating osteogenesis imperfecta Type I, III or IV and to see how well BPS804 is tolerated. Investigators Principal Investigator Kent R. Wehmeier, M.D. Medicine Sub Investigator Marilu M. Jurado Flores, M.D. Medicine